Free Trial

McKesson (MCK) Competitors

McKesson logo
$597.68 -5.83 (-0.97%)
Closing price 02/21/2025 03:59 PM Eastern
Extended Trading
$597.95 +0.27 (+0.05%)
As of 02/21/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MCK vs. COR, CAH, HSIC, PDCO, OMI, HLF, NUS, COSM, HWH, and MEDS

Should you be buying McKesson stock or one of its competitors? The main competitors of McKesson include Cencora (COR), Cardinal Health (CAH), Henry Schein (HSIC), Patterson Companies (PDCO), Owens & Minor (OMI), Herbalife (HLF), Nu Skin Enterprises (NUS), Cosmos Health (COSM), HWH International (HWH), and TRxADE HEALTH (MEDS).

McKesson vs.

McKesson (NYSE:MCK) and Cencora (NYSE:COR) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, community ranking, earnings, analyst recommendations and dividends.

In the previous week, McKesson had 17 more articles in the media than Cencora. MarketBeat recorded 41 mentions for McKesson and 24 mentions for Cencora. McKesson's average media sentiment score of 1.49 beat Cencora's score of 1.30 indicating that McKesson is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
McKesson
34 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Cencora
22 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

McKesson pays an annual dividend of $2.84 per share and has a dividend yield of 0.5%. Cencora pays an annual dividend of $2.20 per share and has a dividend yield of 0.9%. McKesson pays out 13.0% of its earnings in the form of a dividend. Cencora pays out 31.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. McKesson has increased its dividend for 17 consecutive years and Cencora has increased its dividend for 15 consecutive years.

85.1% of McKesson shares are owned by institutional investors. Comparatively, 97.5% of Cencora shares are owned by institutional investors. 0.1% of McKesson shares are owned by company insiders. Comparatively, 10.8% of Cencora shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

McKesson has higher revenue and earnings than Cencora. McKesson is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
McKesson$308.95B0.24$3.00B$21.8427.37
Cencora$293.96B0.16$1.51B$7.0334.35

McKesson has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Cencora has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.

McKesson received 227 more outperform votes than Cencora when rated by MarketBeat users. Likewise, 74.33% of users gave McKesson an outperform vote while only 65.38% of users gave Cencora an outperform vote.

CompanyUnderperformOutperform
McKessonOutperform Votes
973
74.33%
Underperform Votes
336
25.67%
CencoraOutperform Votes
746
65.38%
Underperform Votes
395
34.62%

McKesson has a net margin of 0.82% compared to Cencora's net margin of 0.46%. Cencora's return on equity of 328.62% beat McKesson's return on equity.

Company Net Margins Return on Equity Return on Assets
McKesson0.82% -181.26% 5.34%
Cencora 0.46%328.62%4.23%

McKesson presently has a consensus target price of $645.79, suggesting a potential upside of 8.05%. Cencora has a consensus target price of $277.90, suggesting a potential upside of 15.09%. Given Cencora's higher possible upside, analysts clearly believe Cencora is more favorable than McKesson.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
McKesson
0 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.94
Cencora
0 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.82

Summary

McKesson beats Cencora on 16 of the 22 factors compared between the two stocks.

Get McKesson News Delivered to You Automatically

Sign up to receive the latest news and ratings for MCK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MCK vs. The Competition

MetricMcKessonDrugs, proprietaries, & sundries IndustryMedical SectorNYSE Exchange
Market Cap$74.91B$21.59B$5.77B$20.07B
Dividend Yield0.47%1.37%4.78%3.65%
P/E Ratio27.3712.1826.4634.90
Price / Sales0.241.40455.0215.64
Price / Cash18.3612.7944.0420.85
Price / Book-27.7028.607.634.92
Net Income$3.00B$872.92M$3.18B$1.02B
7 Day Performance0.65%3.24%-1.91%-1.05%
1 Month Performance2.27%-1.10%-0.19%-1.09%
1 Year Performance17.12%-11.36%16.70%13.70%

McKesson Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MCK
McKesson
4.7097 of 5 stars
$597.68
-1.0%
$645.79
+8.0%
+17.8%$74.91B$308.95B27.3751,000Insider Trade
Positive News
COR
Cencora
4.4143 of 5 stars
$243.03
-0.6%
$277.90
+14.3%
+3.4%$46.97B$638.56M34.5746,000Positive News
CAH
Cardinal Health
4.7844 of 5 stars
$126.35
-0.3%
$136.87
+8.3%
+20.2%$30.52B$226.83B23.5748,900Positive News
HSIC
Henry Schein
3.8649 of 5 stars
$76.00
-2.1%
$80.09
+5.4%
+2.9%$9.48B$12.34B31.2825,000Upcoming Earnings
PDCO
Patterson Companies
4.2925 of 5 stars
$31.03
0.0%
$26.57
-14.4%
+11.6%$2.74B$6.57B18.157,600Upcoming Earnings
OMI
Owens & Minor
4.5972 of 5 stars
$7.45
-3.8%
$16.79
+125.5%
-71.4%$574.08M$10.33B-11.4513,700Upcoming Earnings
Analyst Revision
HLF
Herbalife
3.4656 of 5 stars
$5.59
+7.0%
$9.90
+77.2%
-1.3%$563.13M$5.00B6.579,200Earnings Report
Analyst Forecast
Options Volume
News Coverage
Gap Down
High Trading Volume
NUS
Nu Skin Enterprises
3.1264 of 5 stars
$7.54
+17.4%
$6.88
-8.8%
-39.9%$374.57M$1.73B-3.643,700Analyst Revision
High Trading Volume
COSM
Cosmos Health
1.8878 of 5 stars
$0.62
-3.2%
N/A-23.6%$14.41M$53.38M-0.25100
HWH
HWH International
N/A$0.32
-4.2%
N/A-78.0%$10.06MN/A0.00N/ANews Coverage
Negative News
Gap Down
MEDS
TRxADE HEALTH
N/A$3.15
-0.7%
N/A-66.3%$4.43M$7.45M0.0050Gap Up

Related Companies and Tools


This page (NYSE:MCK) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners